Around the world, procurement processes—which are vital to ensuring an affordable, reliable, and high-quality supply of health products—remain fraught with obstacles.
We collected publicly available information, interviewed experts, and used our diverse range of expertise to analyse and model the COVID-19 vaccine portfolio in order to generate predictions about the vaccine portfolio's timeline.